Physician profile
Matthew Chandler
NPI 1568618940
$9,122.24
in general payments reported to CMS, 2019-2025
38 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.26 · 2020: $134 · 2021: $343 · 2022: $794 · 2023: $2,674 · 2024: $2,420 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,763 · Education: $35.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,763.06 |
| Education | $35.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,316.80 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Celgene Corporation | $975.41 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $847.61 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $695.07 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.25 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Boston Scientific Corporation | $441.70 | 2020-2022 | |
| Pfizer INC. | $433.04 | 2022-2025 | |
| Genzyme Corporation | $381.52 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $364.31 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $360.23 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $235.75 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $229.68 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $144.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $106.70 | 2024 | Gi Genius |
| Celltrion USA INC. | $104.26 | 2024-2025 | Zymfentra, Vegzelma |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $102.84 | 2023-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $97.16 | 2022 | |
| Fresenius Kabi USA, LLC | $83.11 | 2023-2025 | Idacio |
| Phathom Pharmaceuticals, INC. | $81.07 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $74.19 | 2024-2025 | Injectafer |
| Sandoz INC. | $57.37 | 2023-2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $53.26 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $48.01 | 2022-2023 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $47.57 | 2024-2025 | Rebyota |
| Nestle Healthcare Nutrition INC. | $44.43 | 2023 | |
| Aimmune Therapeutics, INC. | $44.38 | 2025 | Zenpep |
| Novo Nordisk INC | $29.02 | 2025 | Wegovy |
| Gilead Sciences, INC. | $24.94 | 2024 | |
| Organon LLC | $24.34 | 2025 | Hadlima, Renflexis |
| Covidien LP | $23.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.75 | 2023 | |
| Olympus America INC. | $20.28 | 2023 | Evis Exera Lll Colonovideoscope |
| Alnylam Pharmaceuticals INC. | $17.01 | 2025 | Givlaari |
| Merck Sharp & Dohme LLC | $16.10 | 2024 | Dificid |
| Capsovision, INC. | $15.17 | 2024 | Capsocam Plus |
| Endogastric Solutions, INC | $15.14 | 2024 | Esophyx |
| Allergan, INC. | $15.08 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.